Lansoprazole is superior to ranitidine as maintenance treatment for the prevention of duodenal ulcer relapse

Autor:	D. G. Weir, R. P. H. Thompson, K D Bardhan, J. P. Crowe, P. W. N. Keeling, S. L. Crouch, P. N. Trewby
Rok vydání:	1999
Předmět:	medicine.medical_specialty Chemotherapy Randomization Hepatology business.industry medicine.drug_class medicine.medical_treatment Gastroenterology Lansoprazole Proton-pump inhibitor Ranitidine medicine.anatomical_structure Maintenance therapy Internal medicine medicine Duodenum Pharmacology (medical) Adverse effect business medicine.drug
Zdroj:	Alimentary Pharmacology & Therapeutics. 13:827-832
ISSN:	0269-2813
Popis:	Aim : To compare lansoprazole 30 mg once daily, lansoprazole 15 mg once daily and ranitidine 150 mg once nightly in the prevention of duodenal ulcer relapse in patients whose duodenal ulcers had been previously healed with lansoprazole 30 mg once daily or ranitidine 300 mg nightly. Methods : A double-blind, parallel group, randomized multicentre study conducted in 33 centres in the UK, Eire, Sweden and Australia. Two hundred and nineteen patients with a duodenal ulcer were randomized to receive lansoprazole 30 mg and 217 to receive ranitidine 300 mg for 8 weeks. Patients were then re-randomized to receive lansoprazole 30 mg (122 patients), lansoprazole 15 mg (121 patients) or ranitidine 150 mg (116 patients) for 12 months. All patients had an endoscopically-proven duodenal ulcer at baseline and were considered suitable for long-term maintenance therapy to prevent relapse. Results : Significantly more patients were healed on lansoprazole (98%) compared to ranitidine (89%) (P
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::a863c504504e7e32643ff4ab89c3501c https://doi.org/10.1046/j.1365-2036.1999.00533.x Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.